Catalyst Pharmaceuticals (NASDAQ:CPRX) Downgraded by Zacks Research to “Hold”

Zacks Research lowered shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong-buy rating to a hold rating in a report published on Monday morning,Zacks.com reports.

A number of other analysts have also commented on the company. Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Robert W. Baird downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Finally, Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Trading Down 0.1%

Shares of CPRX stock opened at $31.21 on Monday. The business’s 50-day moving average price is $26.42 and its 200-day moving average price is $24.50. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 0.91 and a beta of 0.72.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada grew its stake in Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after purchasing an additional 60,040 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Catalyst Pharmaceuticals by 5.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock worth $1,749,000 after purchasing an additional 3,800 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Catalyst Pharmaceuticals by 99.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after purchasing an additional 262,392 shares in the last quarter. Finally, Intech Investment Management LLC increased its holdings in Catalyst Pharmaceuticals by 6.5% in the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after purchasing an additional 4,261 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).